Avid Radiopharmaceuticals Announces Positive Interim Results from Phase III Clinical Trial of Amyloid Imaging Agent Florbetapir F18
Posted by | April 15, 2010
Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis of Alzheimer’s disease. Avid is a pioneer in the development of molecular imaging agents for Alzheimer’s disease, which could lead to earlier diagnosis and better evaluation of drugs designed to prevent or reverse amyloid plaque build-up in the brain.
On the heels of this announcement, Avid was featured in the Wall Street Journal by healthcare writer Shirley S. Wang. We are all very excited by these encouraging results, which put Avid on pace to complete its Phase III trial later this year.
Subscribe to Safeguard’s RSS feed to stay up to date on all company and partner company news.
